 So I'm from the National Institute of Environmental Health Sciences and I'm going to give you just a really brief run through of the NIH roadmap epitomics program, which in many ways is kind of the complementary program to encode. So as many of you know, there's lots of different epitomic changes that have been implicated in many human diseases. A lot of these changes occur through normal developmental processes and there's also lots of external influences and environmental exposures that can impact the epigenome as well. So the NIH epitomics roadmap program is really a comprehensive program, a common fund program that has a lot of different complementary components. It's really trying to accelerate the understanding of epitomics in human health and disease through a lot of different new research tools, data sets, and infrastructure. And this is listing a lot of the different components of the roadmap epitomics program. So there is a large research component. Those are mostly R01 grants that are focused on different disease outcomes. There's a discovery of novel epitomic marks. There's a computational analysis component. There's also a technology development component that includes a lot of in vivo epigenomic imaging. And then the reference epigenome mapping consortium is kind of the public resource of the human epigenomics data. And this has really leveraged a pipeline that includes a lot of next generation sequencing technologies to map DNA methylation, histone modifications, chromatin accessibility, and RNA transcripts. And I have down there, I've listed the different mapping center components and the coordination center. So the mapping centers have made epigenomic profiles of many different primary cells and tissues. And this includes the heart, the GI tract, the lung, many brain components, many blood components. And this is in both adult and fetal tissues. And they've also looked a lot of different derived embryonic stem cells as well. And these areas that were selected were carefully trying to represent as many of the normal counterparts of many tissues and organ systems that are frequently involved in human disease. So from these studies, many questions have now been answered about how different human cell types and tissues do differ epigenetically. And there's lots of uses, of course, of this epigenomic information. And I know many of you are using it in many different ways. And it's been encouraging at ASHG to see a lot of uses of the roadmap data. I just wanted to highlight a couple that I think do complement especially the encode use of the data. And one is the marking of functional genomic elements. So along with encode, the roadmap data has really assisted in annotating a lot of different areas of the genome and different cell types. And then the other one is interpreting GWAS hits. And Mike already kind of alluded to this. But we've learned that a lot of the GWAS hits are really in coding regions, non-coding regions, regulatory regions rather, and that a lot of them are in or near enhancer or promoter elements. And that's really impacted the types of functional follow-up studies that a lot of investigators have used and have focused on in recent years in order to interpret the GWAS data. And then I also just wanted to mention that it's been used in recent years to try to better identify different cell types that are involved in particular diseases. So for this particular example in this paper, they were able to show that a number of different immune cells were implicated in Crohn's disease. And so finally, I just wanted to mention that we had a big issue of nature earlier this year that had a lot of different publications, including an integrative analysis reference aptidgenome paper. And I really encourage you to take a look at this issue if you haven't already. It kind of gives you a good idea of the breadth and the depth of this program, and there were a number of other publications in nature-associated journals as well. With that, thank you.